{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:40:37Z","timestamp":1792701637571,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04973-y","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:07:35Z","timestamp":1792656455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational applications and clinical utility of organoids in ovarian cancer: a systematic review"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3485-4960","authenticated-orcid":false,"given":"Reem","family":"ALzahrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha Ali","family":"Alghadmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"4973_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00432-024-05654-0","volume":"150","author":"H Hu","year":"2024","unstructured":"Hu H, Sun C, Chen J, Li Z (2024) Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment. J Cancer Res Clin Oncol 150:146. https:\/\/doi.org\/10.1007\/s00432-024-05654-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"4973_CR2","doi-asserted-by":"publisher","first-page":"1389012","DOI":"10.3389\/fcell.2024.1389012","volume":"12","author":"D Gaebler","year":"2024","unstructured":"Gaebler D, Hachey SJ, Hughes CCW (2024) Microphysiological systems as models for immunologically \u2018cold\u2019 tumors. Front Cell Dev Biol 12:1389012. https:\/\/doi.org\/10.3389\/fcell.2024.1389012","journal-title":"Front Cell Dev Biol"},{"key":"4973_CR3","doi-asserted-by":"publisher","first-page":"1556377","DOI":"10.3389\/fimmu.2025.1556377","volume":"16","author":"R Fu","year":"2025","unstructured":"Fu R, Hu R, Li W, Lv X, Zhao H, Li F (2025) Unveiling drug resistance pathways in high-grade serous ovarian cancer (HGSOC): recent advances and future perspectives. Front Immunol 16:1556377. https:\/\/doi.org\/10.3389\/fimmu.2025.1556377","journal-title":"Front Immunol"},{"key":"4973_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2025.15130","volume":"30","author":"K Alrosan","year":"2025","unstructured":"Alrosan K, Alrosan AZ, Heilat GB, Alrousan AF, Gammoh O, Alqudah A et al (2025) Treatment of ovarian cancer: from the past to the new era (Review). Oncol Lett 30:1\u201328. https:\/\/doi.org\/10.3892\/ol.2025.15130","journal-title":"Oncol Lett"},{"key":"4973_CR5","doi-asserted-by":"publisher","unstructured":"Pierre ME, Kopp RM, Hern\u00e1ndez A, Rodr\u00edguez J, Fletcher A, Ram\u00edrez HM et al (2024) Consenso de expertos basado en la evidencia: perfilamiento y manejo del carcinoma epitelial de ovario de alto grado avanzado. Rev Colomb Obstet Ginecol 75. https:\/\/doi.org\/10.18597\/rcog.4094","DOI":"10.18597\/rcog.4094"},{"key":"4973_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"P Whiting","year":"2011","unstructured":"Whiting P, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529\u2013536. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009","journal-title":"Ann Intern Med"},{"key":"4973_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","volume":"61","author":"D Jelovac","year":"2011","unstructured":"Jelovac D, Armstrong DK (2011) Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 61:183\u2013203. https:\/\/doi.org\/10.3322\/caac.20113","journal-title":"CA Cancer J Clin"},{"key":"4973_CR8","doi-asserted-by":"publisher","first-page":"1367592","DOI":"10.3389\/fonc.2024.1367592","volume":"14","author":"F Guffanti","year":"2024","unstructured":"Guffanti F, Alcaro S, Ganzinelli M, Marra E, Damia G (2024) PARP inhibitors in ovarian cancer: from mechanisms of action to clinical development. Front Oncol 14:1367592. https:\/\/doi.org\/10.3389\/fonc.2024.1367592","journal-title":"Front Oncol"},{"key":"4973_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s13046-021-02139-7","volume":"40","author":"M Tao","year":"2021","unstructured":"Tao M, Wu X (2021) The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing. J Exp Clin Cancer Res 40:338. https:\/\/doi.org\/10.1186\/s13046-021-02139-7","journal-title":"J Exp Clin Cancer Res"},{"key":"4973_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DDL Bowtell","year":"2015","unstructured":"Bowtell DDL, B\u00f6hm S, Ahmed AA, Aspuria P, Bast RC, Beral V et al (2015) Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15:668\u2013679. https:\/\/doi.org\/10.1038\/nrc4019","journal-title":"Nat Rev Cancer"},{"key":"4973_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13046-025-03537-x","volume":"44","author":"L Thorel","year":"2025","unstructured":"Thorel L, Dolivet \u00c9, Morice P, Florent R, Divoux J, Perr\u00e9ard M et al (2025) Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response. J Exp Clin Cancer Res 44:282. https:\/\/doi.org\/10.1186\/s13046-025-03537-x","journal-title":"J Exp Clin Cancer Res"},{"key":"4973_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1158\/2767-9764.crc-22-0337","volume":"2","author":"TY Bowley","year":"2022","unstructured":"Bowley TY, Lagutina IV, Francis C, Sivakumar S, Selwyn R, Taylor EN et al (2022) The RPL\/RPS gene signature of melanoma CTCs associates with brain metastasis. Cancer Res Commun 2:1436\u20131448. https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0337","journal-title":"Cancer Res Commun"},{"key":"4973_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.cd-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ et al (2018) Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov 8:1404\u20131421. https:\/\/doi.org\/10.1158\/2159-8290.cd-18-0474","journal-title":"Cancer Discov"},{"key":"4973_CR14","doi-asserted-by":"publisher","first-page":"912641","DOI":"10.3389\/fmed.2022.912641","volume":"9","author":"GC Napoli","year":"2022","unstructured":"Napoli GC, Figg WD, Chau CH (2022) Functional drug screening in the era of precision medicine. Front Med 9:912641. https:\/\/doi.org\/10.3389\/fmed.2022.912641","journal-title":"Front Med"},{"key":"4973_CR15","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4978004","author":"A Boil\u00e8ve","year":"2024","unstructured":"Boil\u00e8ve A, Cartry J, Andr\u00e9 F, Ducreux M, Jaulin F (2024) Toward the implementation of patient-derived organoids in functional precision medicine. SSRN Electron J. https:\/\/doi.org\/10.2139\/ssrn.4978004","journal-title":"SSRN Electron J"},{"key":"4973_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41698-023-00463-z","volume":"7","author":"E \u00c5kerlund","year":"2023","unstructured":"\u00c5kerlund E, Gudoityt\u0117 G, Moussaud-Lamodi\u00e8re E, Lind O, Bwanika HC, Lehti K et al (2023) The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients. NPJ Precis Oncol 7:111. https:\/\/doi.org\/10.1038\/s41698-023-00463-z","journal-title":"NPJ Precis Oncol"},{"key":"4973_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-023-02809-8","volume":"42","author":"L Thorel","year":"2023","unstructured":"Thorel L, Morice P, Paysant H, Florent R, Babin G, Thomine C et al (2023) Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma. J Exp Clin Cancer Res 42:260. https:\/\/doi.org\/10.1186\/s13046-023-02809-8","journal-title":"J Exp Clin Cancer Res"},{"key":"4973_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00018-022-04395-y","volume":"79","author":"A Ciucci","year":"2022","unstructured":"Ciucci A, Buttarelli M, Fagotti A, Scambia G, Gallo D (2022) Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application. Cell Mol Life Sci 79:364. https:\/\/doi.org\/10.1007\/s00018-022-04395-y","journal-title":"Cell Mol Life Sci"},{"key":"4973_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13046-021-01917-7","volume":"40","author":"C Nero","year":"2021","unstructured":"Nero C, Vizzielli G, Lorusso D, Cesari E, Daniele G, Loverro M et al (2021) Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. J Exp Clin Cancer Res 40:116. https:\/\/doi.org\/10.1186\/s13046-021-01917-7","journal-title":"J Exp Clin Cancer Res"},{"key":"4973_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-021-01426-3","volume":"20","author":"S Pamarthy","year":"2021","unstructured":"Pamarthy S, Sabaawy HE (2021) Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Mol Cancer 20:125. https:\/\/doi.org\/10.1186\/s12943-021-01426-3","journal-title":"Mol Cancer"},{"key":"4973_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12929-024-00994-y","volume":"31","author":"WH Abuwatfa","year":"2024","unstructured":"Abuwatfa WH, Pitt WG, Husseini GA (2024) Scaffold-based 3D cell culture models in cancer research. J Biomed Sci 31:7. https:\/\/doi.org\/10.1186\/s12929-024-00994-y","journal-title":"J Biomed Sci"},{"key":"4973_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, de Witte CJ, L\u00f5hmussaar K, Valle-Incl\u00e1n JE, Hami N, Kester L et al (2019) An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med 25:838\u2013849. https:\/\/doi.org\/10.1038\/s41591-019-0422-6","journal-title":"Nat Med"},{"key":"4973_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-018-0662-9","volume":"11","author":"H Xu","year":"2018","unstructured":"Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K (2018) Organoid technology and applications in cancer research. J Hematol Oncol 11:116. https:\/\/doi.org\/10.1186\/s13045-018-0662-9","journal-title":"J Hematol Oncol"},{"key":"4973_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12967-025-07112-y","volume":"24","author":"H Wang","year":"2026","unstructured":"Wang H, Wang L, Zhu X, He M, Zhong L, Lv Y et al (2026) Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer. J Transl Med 24:55. https:\/\/doi.org\/10.1186\/s12967-025-07112-y","journal-title":"J Transl Med"},{"key":"4973_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41698-021-00168-1","volume":"5","author":"GE Wensink","year":"2021","unstructured":"Wensink GE, Elias SG, Mullenders J, Koopman M, Boj SF, Kranenburg O et al (2021) Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. NPJ Precis Oncol 5:30. https:\/\/doi.org\/10.1038\/s41698-021-00168-1","journal-title":"NPJ Precis Oncol"},{"key":"4973_CR26","doi-asserted-by":"publisher","unstructured":"Hogenson T, Xie H, Hu Y, Graham R, McWilliams R, Gores G (2022) Patient-derived organoids for personalized cancer therapy. J Clin Invest 132. https:\/\/doi.org\/10.1172\/JCI158413","DOI":"10.1172\/JCI158413"},{"key":"4973_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2021.05.026","volume":"517","author":"Y Hu","year":"2021","unstructured":"Hu Y, Sui X, Wang Y, Wang Z, Wang H, Zhang Y (2021) Organoids in gastrointestinal cancers: from bench to clinic. Cancer Lett 517:31\u201343. https:\/\/doi.org\/10.1016\/j.canlet.2021.05.026","journal-title":"Cancer Lett"},{"key":"4973_CR28","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.devcel.2023.04.012","volume":"58","author":"W Senkowski","year":"2023","unstructured":"Senkowski W, Gall-Mas L, Falco MM, Li Y, Lavikka K, Kriegbaum MC et al (2023) A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Dev Cell 58:1106. https:\/\/doi.org\/10.1016\/j.devcel.2023.04.012","journal-title":"Dev Cell"},{"key":"4973_CR29","doi-asserted-by":"publisher","first-page":"12581","DOI":"10.1038\/s41598-020-69488-9","volume":"10","author":"Y Nanki","year":"2020","unstructured":"Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M et al (2020) Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci Rep 10:12581. https:\/\/doi.org\/10.1038\/s41598-020-69488-9","journal-title":"Sci Rep"},{"key":"4973_CR30","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann T, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"4973_CR31","doi-asserted-by":"publisher","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","DOI":"10.1007\/s10654-010-9491-z"},{"key":"4973_CR32","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s13577-022-00827-w","volume":"36","author":"Y Ito","year":"2022","unstructured":"Ito Y, Kondo J, Masuda M, Matsuzaki S, Onuma K, Kanda M et al (2022) Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs. Hum Cell 36:752\u2013761. https:\/\/doi.org\/10.1007\/s13577-022-00827-w","journal-title":"Hum Cell"},{"key":"4973_CR33","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1186\/s12885-025-14811-8","volume":"25","author":"P Nikeghbal","year":"2025","unstructured":"Nikeghbal P, Zamanian D, Burke D, Steinkamp MP (2025) Organoid models established from primary tumors and patient-derived xenograft tumors reflect platinum sensitivity of ovarian cancer patients. BMC Cancer 25:1459. https:\/\/doi.org\/10.1186\/s12885-025-14811-8","journal-title":"BMC Cancer"},{"key":"4973_CR34","doi-asserted-by":"publisher","first-page":"13208","DOI":"10.3390\/ijms241713208","volume":"24","author":"AE Arias-Diaz","year":"2023","unstructured":"Arias-Diaz AE, Ferreiro-Pantin M, Barbaz\u00e1n J, P\u00e9rez-B\u00e9liz E, Ruiz-Ba\u00f1obre J, Casas-Arozamena C et al (2023) Ascites-derived organoids to depict platinum resistance in gynaecological serous carcinomas. Int J Mol Sci 24:13208. https:\/\/doi.org\/10.3390\/ijms241713208","journal-title":"Int J Mol Sci"},{"key":"4973_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13048-021-00893-6","volume":"14","author":"J Bi","year":"2021","unstructured":"Bi J, Wang Y, Chen X, Yu L, Liu S, Liu P (2021) Patient-derived organoids for ovarian cancer: a promising model for drug screening and personalized medicine. J Ovarian Res 14:142. https:\/\/doi.org\/10.1186\/s13048-021-00893-6","journal-title":"J Ovarian Res"},{"key":"4973_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41698-025-01080-8","volume":"9","author":"E Koedoot","year":"2025","unstructured":"Koedoot E, van der Meer D, van Altena AM, Ceton L, Sijsenaar T, Montero MG et al (2025) Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer. NPJ Precis Oncol 9:306. https:\/\/doi.org\/10.1038\/s41698-025-01080-8","journal-title":"NPJ Precis Oncol"},{"key":"4973_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41698-023-00379-8","volume":"7","author":"HJ Gray","year":"2023","unstructured":"Gray HJ, Chatterjee P, Rosati R, Appleyard L, Durenberger G, Diaz RL et al (2023) Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing. NPJ Precis Oncol 7:45. https:\/\/doi.org\/10.1038\/s41698-023-00379-8","journal-title":"NPJ Precis Oncol"},{"key":"4973_CR38","doi-asserted-by":"publisher","first-page":"106232","DOI":"10.1016\/j.phrs.2022.106232","volume":"179","author":"M Tao","year":"2022","unstructured":"Tao M, Sun F, Wang J, Wang Y, Zhu H, Chen M et al (2022) Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer. Pharmacol Res 179:106232. https:\/\/doi.org\/10.1016\/j.phrs.2022.106232","journal-title":"Pharmacol Res"},{"key":"4973_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jare.2025.08.009","volume":"83","author":"E Cavarzerani","year":"2025","unstructured":"Cavarzerani E, Caligiuri I, Bartoletti M, Corona G, Perin T, Palumbo A et al (2025) Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses. J Adv Res 83:379\u2013390. https:\/\/doi.org\/10.1016\/j.jare.2025.08.009","journal-title":"J Adv Res"},{"key":"4973_CR40","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3390\/pharmaceutics14122709","volume":"14","author":"M Londo\u00f1o-Berr\u00edo","year":"2022","unstructured":"Londo\u00f1o-Berr\u00edo M, Castro C, Ca\u00f1as AI, Ort\u00edz I, Osorio M (2022) Advances in tumor organoids for the evaluation of drugs: a bibliographic review. Pharmaceutics 14:2709. https:\/\/doi.org\/10.3390\/pharmaceutics14122709","journal-title":"Pharmaceutics"},{"key":"4973_CR41","doi-asserted-by":"publisher","first-page":"100866","DOI":"10.1016\/j.crmeth.2024.100866","volume":"4","author":"R Crouigneau","year":"2024","unstructured":"Crouigneau R, Li Y, Auxillos J, Gon\u00e7alves-Alves E, Marie R, Sandelin A et al (2024) Mimicking and analyzing the tumor microenvironment. Cell Rep Methods 4:100866. https:\/\/doi.org\/10.1016\/j.crmeth.2024.100866","journal-title":"Cell Rep Methods"},{"key":"4973_CR42","doi-asserted-by":"publisher","first-page":"19103","DOI":"10.1038\/srep19103","volume":"6","author":"M Zanoni","year":"2016","unstructured":"Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R et al (2016) 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep 6:19103. https:\/\/doi.org\/10.1038\/srep19103","journal-title":"Sci Rep"},{"key":"4973_CR43","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/cells14100732","volume":"14","author":"S Shah","year":"2025","unstructured":"Shah S, D\u2019Souza GGM (2025) Modeling tumor microenvironment complexity in vitro: spheroids as physiologically relevant tumor models and strategies for their analysis. Cells 14:732. https:\/\/doi.org\/10.3390\/cells14100732","journal-title":"Cells"},{"key":"4973_CR44","doi-asserted-by":"publisher","unstructured":"Wang L, Hu D, Xu J, Hu J, Wang Y (2023) Complex in vitro model: a transformative model in drug development and precision medicine. Clin Transl Sci 17. https:\/\/doi.org\/10.1111\/cts.13695","DOI":"10.1111\/cts.13695"},{"key":"4973_CR45","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1021\/acsbiomaterials.7b00069","volume":"4","author":"MF Gencoglu","year":"2017","unstructured":"Gencoglu MF, Barney LE, Hall CL, Brooks E, Schwartz AD, Corbett DC et al (2017) Comparative study of multicellular tumor spheroid formation methods and implications for drug screening. ACS Biomater Sci Eng 4:410\u2013420. https:\/\/doi.org\/10.1021\/acsbiomaterials.7b00069","journal-title":"ACS Biomater Sci Eng"},{"key":"4973_CR46","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"Thorel L, Perr\u00e9ard M, Florent R, Divoux J, Coffy S, Vincent A et al (2024) Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med 56:1531\u20131551. https:\/\/doi.org\/10.1038\/s12276-024-01272-5","journal-title":"Exp Mol Med"},{"key":"4973_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13048-019-0577-2","volume":"12","author":"S Dumont","year":"2019","unstructured":"Dumont S, Jan \u017d, Heremans R, Gorp TV, Vergote I, Timmerman D (2019) Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review. J Ovarian Res 12:105. https:\/\/doi.org\/10.1186\/s13048-019-0577-2","journal-title":"J Ovarian Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04973-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04973-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04973-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:03:09Z","timestamp":1792699389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04973-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4973"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04973-y","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"121"}}